Door-to-door cold chain matters because temperature-sensitive products are exposed to the highest risk not during long-distance transport, but during handovers, storage, and transitions between logistics partners.
Maintaining continuous temperature protection from the shipper’s loading dock to the consignee’s facility reduces excursions, product loss, security risk, and compliance issues.
Door-to-door cold chain refers to a logistics approach where temperature protection is maintained continuously from origin to final destination, without unloading, repacking, or transferring products into different temperature-control systems along the way.
This contrasts with segmented cold chains, where protection may stop at airports, freight forwarder hubs, or warehouse interfaces, and is resumed later using different equipment or vehicles.
Temperature-sensitive pharmaceuticals, biologics, vaccines, and specialty medicines face risk at every stage of transit. The majority of excursions occur not because temperature-control technology fails, but because protection is interrupted.
Following the product journey highlights where these risks emerge.
Risk factors
At origin, temperature protection often depends on correct preparation and availability of equipment. Any delay or deviation at this stage can reduce the remaining thermal margin for the rest of the journey.
Solutions designed for door-to-door use (like SkyCell's hybrid container) reduce the need for preconditioning steps, charging cycles, or specialized storage zones, lowering early-stage risk.
Risk factors
When products are transferred between trucks, containers, or vehicles, exposure risk increases. Each transfer introduces potential delays, human error, or infrastructure gaps.
Maintaining the same protective system through ground transport avoids unnecessary transfers and preserves temperature stability.
Airports are consistently one of the highest-risk environments for temperature-sensitive products.
Risk factors
According to IATA, over half of all temperature excursions occur at airports.
Door-to-door cold chain solutions that do not rely on airport infrastructure and tolerate long dwell times significantly reduce exposure during this critical phase.
Risk factors
After arrival, products are often unloaded and transferred into different systems before final delivery. This handover is frequently under-controlled and poorly visible.
Maintaining continuous protection through customs and onward transport reduces the likelihood of temperature deviations and undocumented exposure.
This leg is often underestimated but highly risky.
Risk factors
Many cold chains lose protection just before delivery, when products are closest to patient use. Often, products are removed from ULD containers, exposing them to ambient temperatures.
Door-to-door solutions ensure that temperature protection and tracking extend all the way to the receiving facility, preserving product integrity until handover. Non-ULD containers, like hybrid containers, can protect products at this vital stage.
Maintaining continuous temperature protection across all stages delivers several benefits:
Reliability increases as complexity and segmentation decrease.
For biologics, cell and gene therapies, vaccines, and specialty medicines, door-to-door cold chain is not just operationally convenient. It is critical for:
As therapies become more sensitive and valuable, end-to-end protection becomes a baseline requirement rather than a premium option.
Door-to-door cold chain and cold corridor logistics are often treated as interchangeable, but they address temperature risk in fundamentally different ways.
Cold corridor logistics focuses on maintaining temperature control only within predefined segments of the supply chain. These corridors typically include:
Temperature-controlled warehouses
Designated airport zones
Temperature-controlled vehicles on specific legs
Within the corridor, temperature conditions are managed and validated. Outside the corridor, products are often transferred, staged, or temporarily stored under different levels of control.
Cold corridors rely heavily on infrastructure availability, coordination between partners, and precise timing to remain effective.
Cold corridor models work well when infrastructure is consistent and delays are minimal. Risk increases when:
Shipments are delayed between corridor segments
Infrastructure such as plugs or temperature-controlled zones is unavailable
Products are transferred or repacked between systems
Door-to-door cold chain reduces these risks by eliminating dependency on corridor boundaries and minimizing handling events.
| Aspect | Cold corridor logistics | Door-to-door cold chain |
| Temperature protection | Maintained within defined segments | Maintained continuously end to end |
| Infrastructure dependency | High | Low |
| Exposure during delays | Higher | Lower |
| Visibility and traceability | Fragmented | Continuous |
| Suitability for high-value products | Route-dependent | High |
Cold corridors are often used for:
Predictable routes with mature infrastructure
High-volume shipments with stable schedules
Environments where partners operate within the same network
Door-to-door cold chain is preferred for:
High-value or irreplaceable products
Long-haul international shipments
Routes with variable infrastructure or frequent delays
Products with low tolerance for excursions
As pharmaceutical products become more sensitive and valuable, the limits of corridor-based protection become more visible. Door-to-door cold chain shifts the responsibility for temperature protection from locations to the shipment itself, reducing complexity and improving reliability.